T. Rowe Price Investment Management Inc. Sells 137,423 Shares of Centessa Pharmaceuticals plc (NASDAQ:CNTA)

T. Rowe Price Investment Management Inc. cut its stake in shares of Centessa Pharmaceuticals plc (NASDAQ:CNTA - Free Report) by 3.9% during the 4th quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The fund owned 3,418,600 shares of the company's stock after selling 137,423 shares during the quarter. T. Rowe Price Investment Management Inc. owned 2.59% of Centessa Pharmaceuticals worth $57,262,000 as of its most recent filing with the Securities and Exchange Commission.

Several other hedge funds and other institutional investors also recently made changes to their positions in CNTA. Franklin Resources Inc. grew its holdings in shares of Centessa Pharmaceuticals by 99.1% during the 3rd quarter. Franklin Resources Inc. now owns 2,302,546 shares of the company's stock valued at $38,360,000 after purchasing an additional 1,145,823 shares during the last quarter. Price T Rowe Associates Inc. MD grew its holdings in shares of Centessa Pharmaceuticals by 14.6% during the 4th quarter. Price T Rowe Associates Inc. MD now owns 5,364,392 shares of the company's stock valued at $89,854,000 after purchasing an additional 685,371 shares during the last quarter. Lord Abbett & CO. LLC bought a new stake in shares of Centessa Pharmaceuticals during the 3rd quarter valued at approximately $4,305,000. Diadema Partners LP bought a new stake in shares of Centessa Pharmaceuticals during the 4th quarter valued at approximately $2,209,000. Finally, ADAR1 Capital Management LLC grew its holdings in shares of Centessa Pharmaceuticals by 561.0% during the 4th quarter. ADAR1 Capital Management LLC now owns 154,027 shares of the company's stock valued at $2,580,000 after purchasing an additional 130,725 shares during the last quarter. 82.01% of the stock is owned by institutional investors.

Insiders Place Their Bets

In other news, insider Karen M. Anderson sold 30,526 shares of the stock in a transaction dated Friday, February 7th. The shares were sold at an average price of $19.03, for a total transaction of $580,909.78. Following the transaction, the insider now owns 54,322 shares of the company's stock, valued at $1,033,747.66. This represents a 35.98 % decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. Also, CTO Tia L. Bush sold 11,000 shares of the firm's stock in a transaction dated Monday, February 3rd. The shares were sold at an average price of $16.86, for a total transaction of $185,460.00. Following the completion of the transaction, the chief technology officer now directly owns 121,503 shares in the company, valued at approximately $2,048,540.58. The trade was a 8.30 % decrease in their position. The disclosure for this sale can be found here. Over the last ninety days, insiders sold 219,513 shares of company stock worth $3,576,685. 11.59% of the stock is currently owned by company insiders.

Analyst Upgrades and Downgrades

CNTA has been the topic of several recent research reports. Morgan Stanley reiterated an "overweight" rating and set a $27.00 target price on shares of Centessa Pharmaceuticals in a research report on Friday, March 7th. TD Cowen initiated coverage on shares of Centessa Pharmaceuticals in a research report on Tuesday, January 7th. They set a "buy" rating on the stock. Piper Sandler initiated coverage on shares of Centessa Pharmaceuticals in a research report on Monday, March 31st. They set an "overweight" rating and a $38.00 target price on the stock. Finally, Guggenheim reiterated a "buy" rating and set a $28.00 target price on shares of Centessa Pharmaceuticals in a research report on Wednesday, March 26th. Eight investment analysts have rated the stock with a buy rating, According to MarketBeat, the stock currently has an average rating of "Buy" and an average target price of $27.71.

Centessa Pharmaceuticals Trading Up 0.2 %

Shares of NASDAQ CNTA traded up $0.03 during midday trading on Thursday, reaching $13.74. The stock had a trading volume of 194,551 shares, compared to its average volume of 609,248. The firm has a market cap of $1.83 billion, a price-to-earnings ratio of -8.97 and a beta of 1.53. Centessa Pharmaceuticals plc has a twelve month low of $7.75 and a twelve month high of $19.09. The company has a debt-to-equity ratio of 0.15, a quick ratio of 21.52 and a current ratio of 21.52. The company's 50 day moving average price is $14.26 and its 200 day moving average price is $15.83.

Centessa Pharmaceuticals (NASDAQ:CNTA - Get Free Report) last issued its quarterly earnings results on Monday, March 24th. The company reported ($0.34) earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($0.38) by $0.04. As a group, sell-side analysts expect that Centessa Pharmaceuticals plc will post -1.6 EPS for the current year.

Centessa Pharmaceuticals Company Profile

Centessa Pharmaceuticals plc, a clinical-stage pharmaceutical company, discovers, develops, and delivers medicines for patients. Its products pipeline includes SerpinPC, an activated protein C inhibitor for the treatment of hemophilia A and B; and ORX750, an orally administered OX2R agonist for the treatment of narcolepsy and other sleep disorders.